Find Academic Supervisors

Jason V WallachView profile

Assistant Professor

• Pharmacology
• Toxicology
• Medicinal Chemistry
• +7 more

Jason V Wallach serves as an Assistant Professor of Practice in the Department of Pharmaceutical Sciences within the School of Health Professions. He maintains a dual appointment at the Substance Use Disorders Institute, focusing on medical cannabis research and substance use disorder curriculum development. His office is located in the Pharmacology and Toxicology Center (Room 236) with contact number 215-596-8806. His educational credentials include a PhD in Pharmacology and Toxicology from the University of the Sciences and a BS in Cell and Molecular Biology from Indiana University of Pennsylvania. Dr Wallach's research program centers on analytical and pharmacological characterization of synthetic psychoactive drugs ( SPDs ) and "legal highs," with significant contributions to understanding lysergamides, diphenidine analogues, and novel dissociative agents. His therapeutic development work targets neuropathic pain , neurodegenerative diseases , depression , and cancer through structure-activity relationship studies, multi-target drug design, and biased ligand development. This dual focus bridges forensic toxicology and pharmaceutical innovation. His publication record (2012-2017) reveals consistent contributions to psychoactive substance research, particularly in analytical methodologies for novel compounds and receptor-targeted therapeutics. Key trends include lysergamide characterization , dissociative agent pharmacology , and HDAC inhibitor development , primarily published in Drug Testing and Analysis and PLoS One . Dr Wallach teaches Laboratory Biomethods, Pharmacology and Toxicology Laboratory Techniques, Psychopharmacology, Pathology, Simulated Physiology Labs, and Toxicology courses. His institutional affiliations with the Pharmacology and Toxicology Center and Substance Use Disorders Institute facilitate integrated research-education initiatives in pharmaceutical sciences and substance use disorders.

Hari ArthanariView profile

Associate Professor

• Structural Biology
• Biochemistry
• Biophysics
• +5 more

Hari Arthanari is an Associate Professor in the Department of Biological Chemistry and Molecular Pharmacology at Harvard Medical School . His research focuses on protein-protein interactions and transcriptional Regulation in disease contexts, utilizing NMR spectroscopy , biophysical assays , and cell-based models . He operates the Arthanari Laboratory at Dana-Farber Cancer Institute, with a lab size of 5-10 members. Develops novel NMR methods for fragment screening and metabolite analysis Investigates transcriptional condensates and translation machinery dysregulation in cancer Applies integrative structural biology to therapeutic target discovery Research trends in his publications highlight therapeutic targeting of protein interactions across diverse diseases including cancer and viral infections . His work spans method development for NMR experiments, metabolomics marker identification , and structural characterization of both viral and human proteins. Articles frequently employ techniques like fluorine NMR , 15N TROSY experiments , and computational screening for drug candidate discovery. Scientific awards or formal recognition were not explicitly mentioned in the provided texts. His lab's publications emphasize collaborative multi-institute research and open-source drug discovery platforms , though no specific student advising or grant details were extracted. The Arthanari Lab (website: artlab.dana-farber.org) maintains focus on structural and functional characterization of proteins involved in disease mechanisms, particularly through NMR-derived metabolomics data and protein-ligand interaction identification .

• Immunology
• Cancer Immunotherapy
• Tumor Immunology
• +3 more

Todd Triplett serves as Assistant Professor in the Department of Immunotherapeutics and Biotechnology at Texas Tech University Health Sciences Center's School of Pharmacy, where his research integrates immunology and oncology to address cancer mechanisms and immune responses. Education: PhD in Immunology, Oregon Health and Science University (2012) BS in Biology, St. Edward's University (2006) His work centers on cancer immunotherapy , particularly T-cell acute lymphoblastic leukemia (T-ALL) and solid tumors, with significant contributions to understanding IDO-mediated immune suppression and kynurenine pathway dynamics. Recent research extends to infectious disease immunology , analyzing longitudinal immune trajectories in COVID-19 patients through the IMPACC consortium, and investigating myeloid cell roles in tumor microenvironments. Publication trends (2020-2024) reveal concentrated efforts in translational applications: HDAC inhibitors (bocodepsin) for immunotherapy combinations, immune checkpoint blockade in gastrointestinal cancers, and mechanistic studies of viral immune responses. These reflect multi-institutional collaborations focused on clinical translation. Scientific Awards: No major awards documented in current profile While specific advising relationships or grant details are unlisted, his involvement in first-in-human clinical trials (e.g., bocodepsin) and large consortia like IMPACC indicates active grant-supported research. Collaborative networks span cancer immunology and pandemic response initiatives. Dr. Triplett participates in cross-institutional teams including the IMPACC study for SARS-CoV-2 research and TTUHSC-based groups developing novel immunotherapies, with recent work emphasizing rational drug combinations for solid tumors and leukemia.

Sudarshan AnandView profile

Assistant Professor

• Cancer
• Tumor Microenvironment
• MicroRNA
• +6 more

Dr. Sudarshan Anand is an Assistant Professor in the Department of Cell, Developmental and Cancer Biology at Oregon Health & Science University (OHSU) School of Medicine, a position he has held since March 2014. His research program focuses on how non-coding RNAs shape tumor responses to DNA-damaging therapies, with emphasis on breast and colorectal cancers. Education: PhD in Immunology, Johns Hopkins University School of Medicine, 2007 Postdoctoral Scholar, Moores Cancer Center, University of California, San Diego, 2007-2014 Research Interests: Dr. Anand's laboratory investigates the role of microRNAs and non-coding RNAs in the tumor microenvironment, particularly in tumor blood vessels and immune cells. His work employs preclinical mouse models, human patient samples, and cell culture systems to develop therapeutic strategies and identify biomarkers for patient stratification. Key areas include radiation therapy response mechanisms, angiogenesis regulation, and nucleic acid sensing pathways in cancer. Publication Trends: Analysis of Dr. Anand's 15 most recent publications (2017-2024) reveals a consistent focus on microRNA regulation in colorectal cancer and tumor vasculature. His work bridges DNA damage response mechanisms with immunotherapy applications, showing increasing emphasis on early-onset cancer subtypes, microbiome interactions, and vascular normalization strategies to enhance drug delivery. Key recurring themes include RIG-I signaling, endothelial dysfunction, and combinatorial therapeutic approaches. Lab and Team: The Anand Lab utilizes multidisciplinary approaches to elucidate tumor microenvironment dynamics, with particular expertise in nucleic acid sensing pathways and endothelial cell biology. The team's research directly informs clinical translation efforts in radiation oncology and immunotherapy, focusing on biomarker discovery and therapeutic targeting of RNA-mediated mechanisms in cancer progression.

• Chemical Biology
• Catalysis
• Cyclic peptides
• +6 more

Andrea Robinson is a Professor in the School of Chemistry at Monash University and a member of the Victorian Heart Institute (VHI). Her research focuses on chemical biology, catalysis, cyclic peptides, disulfide replacement, and renewable chemistry. She has led numerous high-impact projects, including advancements in drug-eluting medical devices, toxin structure-function analysis, and sustainable drug discovery. Notable achievements include the development of novel photo-angioplasty devices and dicarba peptide analogs with enhanced therapeutic efficacy. Research Interests Her work bridges organic synthesis, medicinal chemistry, and biotechnology. Key areas include: - Design of bioactive peptides and peptidomimetics for pain management and diabetes treatment - Sustainable chemical processes using renewable feedstocks - Metathesis-catalyzed peptide synthesis techniques - Development of photothermal cancer theranostics - Exploring fungal pigments and their industrial applications Awards - Dean’s Excellence in Teaching Awards (2017) - Faculty of Science, Dean's Excellence in Teaching Awards (2017) - From grave to cradle: Hunting new antimicrobials through sustainable drug discovery Award (2022) Grants & Projects - ARC Training Centre for Advanced Radiochemical Technologies (2024–2029) - Collaborations on 18F-radiolabeling for cancer diagnosis (University of Melbourne, Cyclotek) - Development of novel chelating agents for medical imaging (2025–2028) - Agricultural pest monitoring systems using night vision technology (DAFF-funded) Labs & Teams Dr. Robinson leads research teams within the School of Chemistry and collaborates with the Victorian Heart Institute. Her lab specializes in: - Peptide synthesis and characterization - Metathesis reaction development - Biomedical device prototyping - Sustainable chemical engineering processes

Xinyun JianView profile

Research Fellow

• Natural Products Discovery
• Antibiotics
• Anti-cancer Drugs
• +3 more

Xinyun Jian is a Research Fellow in the Department of Biochemistry & Molecular Biology at Monash University. Their research focuses on the chemistry and biology of bioactive natural products, including antibiotics, anticancer agents, and agrichemicals. They employ interdisciplinary approaches such as genomics-driven discovery, biosynthetic pathway elucidation, and bioengineering to create novel natural product derivatives. Education: PhD in Chemistry (2014), University of Warwick, UK MSc in Microbial and Biochemical Pharmacy (Bioengineering of aminoglycosides), Wuhan University, China Research Interests: Genomics-driven discovery of novel bioactive natural products Mechanistic characterization of enzymes in biosynthesis pathways Engineering biosynthetic pathways for antibiotic diversification Recent Projects: Primary Chief Investigator (2025–2026): 'Unlocking the Potential of Soil Bacteria to Combat Drug-Resistant Fungal Pathogens' Publications Trends: Recent work emphasizes enzymatic mechanisms in polyketide and nonribosomal peptide systems, with a focus on antibiotic skeletal diversification, glycodiversification of aminoglycosides, and HDAC inhibitor design. Articles highlight interdisciplinary methods to address antibiotic resistance and anticancer drug development. Labs/Teams: Active in Monash University's Biochemistry & Molecular Biology department, collaborating on microbial natural product research and enzymatic biosynthesis.

• Cancer Genomics
• Tumor Immunology
• Colorectal Cancer
• +5 more

Dr. David Church is a researcher at the Centre for Human Genetics, University of Oxford, based at the Henry Wellcome Building of Genomic Medicine. He is affiliated with Brasenose College and collaborates with prominent researchers including Ian Tomlinson and Dr. Claire Palles at Oxford, as well as international collaborators at Leiden University Medical Centre and University of Zurich. Dr. Church's research focuses on tumor-immune system interactions, particularly in cancers with high mutational loads from polymerase proofreading domain mutations. His work demonstrates that ultramutated POLE-mutant colorectal and endometrial cancers have excellent prognoses due to strong anti-tumor T cell responses against numerous neoantigens. His research spans cancer genomics, immunotherapy mechanisms, and molecular classification of gastrointestinal and gynecological cancers. Analysis of Dr. Church's publications reveals consistent focus on mismatch repair-deficient and POLE-mutant cancers across multiple tumor types. His work integrates genomic analysis with immune profiling to understand tumor evolution, immune evasion mechanisms, and biomarker development for immunotherapy response. Key themes include molecular classification systems, tumor microenvironment characterization, and the development of precision medicine approaches for cancer treatment. Dr. Church leads significant collaborative efforts including the RAINBO clinical trial program, which investigates molecular class-directed adjuvant treatment strategies for endometrial cancer through four international clinical trials. His research has direct implications for treatment de-escalation in favorable prognosis subtypes and novel therapeutic approaches for immunotherapy-resistant cancers.

• Medicinal Chemistry
• Epigenetics
• Cancer Drug Development
• +4 more

Prof. Dr. Finn Hansen is a Professor of Pharmacy at the University of Bonn, affiliated with the Department of Pharmacy. His research focuses on developing novel chemical tools to combat chemoresistance in cancer, particularly through the design of selective histone deacetylase (HDAC) inhibitors, protein-protein interaction inhibitors, and chimeric small molecules like PROTACs. The Hansen Group employs advanced synthetic methodologies including solid-phase and microwave-assisted synthesis to create innovative therapeutic compounds. Research Interests: Medicinal Chemistry Epigenetic Modulation PROTAC Technology Cancer Pharmacology Multi-Target Drug Design Laboratory Activities: The group specializes in synthesizing small molecules and peptidomimetics, followed by biological evaluation in target-based and phenotypic assays to analyze structure-activity relationships. Their work bridges synthetic chemistry and translational oncology, with a focus on overcoming treatment resistance mechanisms.

E. Ricky ChanView profile

Academic

• Bioinformatics
• Genomics
• Immunology
• +4 more

E. Ricky Chan, PhD is an Instructor in the Department of Population and Quantitative Health Sciences at Case Western Reserve University School of Medicine. He serves as Director of the Bioinformatics Core at the Institute for Computational Biology. His work integrates genomics, computational biology, and systems biology to study immune mechanisms, metabolic pathways, and microbiome interactions. Dr. Chan holds a PhD from Case Western Reserve University. His research focuses on translational applications of big data analytics in precision medicine, with emphasis on inflammatory bowel disease, cancer biology, and infectious diseases. Recent work includes groundbreaking studies on GSDMB's role in IBD epithelial repair, microbiome metabolic interactions, and synthetic lethality in cancer therapy. Key research trends include multi-omic spatial analysis of neuroinflammation, transcriptomic profiling of drug resistance mechanisms, and leveraging genomic data to understand disease progression. His studies have identified critical biomarkers like the NRF2 gene set and MBOAT7-driven lipid pathways. Current projects involve developing computational tools for viral genomic surveillance and improving microelectrode implant biocompatibility. Dr. Chan leads the Bioinformatics Core supporting over 50 research groups, providing expertise in next-gen sequencing analysis and machine learning applications. His team bridges basic research and clinical translation through collaborative initiatives in immunology, oncology, and metabolic disorders.

• Phenotypic assays for drug discovery
• Fibroproliferative diseases
• Erectile dysfunction
• +4 more

Selim Cellek is Professor of Health and Biomedicine at Anglia Ruskin University (ARU), where he leads the Drug Discovery Group within the Medical Technology Research Centre (MTRC). He is affiliated with the Faculty of Health, Medicine and Social Care, specifically the School of Allied Health and Social Care. His research bridges pharmacology, urology, and translational medicine. Education: MD, Hacettepe University PhD Pharmacology, University of London Research Focus: Professor Cellek specializes in phenotypic drug discovery, fibroproliferative diseases, and urogenital pathophysiology. Key areas include diabetic autonomic neuropathy, Peyronie’s disease, nitrergic neurotransmission, and the development of cell-based assays for novel therapeutics. Publication Trends: His 15 most recent articles (2009–2015) concentrate on urogenital disorders (erectile dysfunction, Peyronie’s disease), diabetic complications, and gastrointestinal pharmacology. Methodologically, they emphasize translational models, drug discovery assays, and neurovascular mechanisms. Awards & Fellowships: Fellowship, British Pharmacological Society Fellowship, European Society for Sexual Medicine Professional Engagement: He consults for the pharmaceutical industry on drug development for urogenital, gastrointestinal, and diabetic neuropathy indications.

Attila A. SeyhanView profile

Adjunct Associate Professor

• Cancer Therapeutics
• Epigenetics
• Functional Genomics
• +17 more

Attila A. Seyhan is an Adjunct Associate Professor of Pathology and Laboratory Medicine at the Warren Alpert Medical School, Brown University. He serves as Director of Translational Oncology Operations at the Brown University Cancer Center and Lifespan Health System. His career spans academia (Brown University, Fox Chase Cancer Center, Florida Hospital, Sanford Burnham Prebys), pharmaceutical sectors (Pfizer, Wyeth), and biotechnology (Open Biosystems, Dharmacon). His collaborative efforts bridge clinicians, scientists, regulatory teams, and industry partners. Education: PhD in Biological Sciences (NATO Science Fellowship) from Michigan Technological University (1993), BS in Biology from Hacettepe University (1986). Postdoctoral Training: Ferritin gene regulation at University of Paris VII (1993-1995); Hairpin ribozyme biochemistry at University of Vermont (1995-1999). Research Interests: Focused on RNA biology, epigenetics, and translational oncology. Key areas include RNA therapeutics (siRNA, miRNA, ribozymes), cancer drug resistance mechanisms, and biomarker discovery for autoimmune/metabolic diseases. His work spans glioblastoma, prostate cancer, colorectal cancer, and pancreatic cancer. Article Trends: Recent publications emphasize drug synergy (ONC201/206 with HDAC/AR inhibitors), TRAIL pathway modulation, liquid biopsy biomarkers (miRNA in GBM, diabetes, lupus), and overcoming translational research barriers. Topics intersect epigenetics, immunotherapy, and AI in precision medicine. Scientific Awards: NATO Science Fellowship (1988-1991) Young Investigator Award (1999) Pfizer Excellence Awards (2013) CalTIP Award (2000) Wyeth/Pfizer Long-Term Incentive Plan (2009-2012) Florida Hospital Certificate of Appreciation (2014) Advising & Grants: As PI/co-PI, he secured NIH/DOD funding for RNAi/shRNA libraries, epigenetic cancer targets, and diabetes biomarkers. His work led to patents (e.g., miRNA-based therapies) and influenced clinical trials (neratinib/paclitaxel combination). Labs & Teams: Leads the Translational Oncology Operations at Brown University Cancer Center. Previously directed Functional Genomics at Wyeth/Pfizer and Translational Research at Florida Hospital. Collaborates with multi-institutional teams (Brown, MIT, Sanford Burnham Prebys).

Angelo KeramidasView profile

Research Fellow

• Neurosciences
• Zoology
• Ion Channels
• +3 more

Dr. Angelo Keramidas is a Senior Research Fellow at the University of Queensland , affiliated with the Institute for Molecular Bioscience. His research focuses on ion channels in health and disease, particularly GABA-A, glycine, and glutamate (NMDA) receptors implicated in neurological disorders like epilepsy, autism, and neurodevelopmental conditions. Projects: Investigating receptor variants in epilepsy/autism, glutamate receptors in developmental delay, and venom peptide modulation of sodium channels. Techniques: Patch-clamp electrophysiology, venom peptide analysis, and functional characterization of ion channel variants. He collaborates with biophysicists, clinicians, and geneticists across Australia, USA, and Europe. Current funding includes an ARC Discovery Project (2023-2026) and industry partnerships.

Kimberly BrienView profile

Associate Professor

• Organometallic Chemistry
• Medicinal Chemistry
• Catalysis
• +3 more

Kimberly Brien serves as an Associate Professor of Chemistry at Rhodes College in Memphis, Tennessee, where she leads an active research laboratory focused on organometallic chemistry applications in anti-cancer drug development and catalysis of organic reactions. Her academic credentials include: Post-doctoral Researcher: Hope College Ph.D.: Texas Christian University M.S.: Baylor University B.S.: Texas Lutheran University Dr. Brien's research program centers on two primary initiatives: synthesizing main-group derivatives of suberoylanilide hydroxamic acid (SAHA) to develop selective histone deacetylase (HDAC) inhibitors with reduced off-target effects for improved cancer therapy, and investigating metal complexes of 2,6-bis-hydrazinopyridine (BHP) derivatives to create novel tridentate ligands for catalytic applications. Her work bridges synthetic organic chemistry, inorganic chemistry, and medicinal pharmacology through innovative molecular design. Analysis of her 2005-2013 publications reveals consistent interdisciplinary contributions spanning cancer drug development (HDAC inhibitors, chalcone analogs, DNA-binding polyamides) and inorganic materials science (bismuth complexes, ligand characterization). Key trends include structural optimization for biological activity, X-ray crystallographic validation of novel compounds, and exploration of main-group metal applications in medicinal chemistry. No scientific awards were documented in the source materials. Dr. Brien mentors undergraduate researchers in her laboratory, though specific student names are unlisted. Grant funding details were not provided in the available text. The Brien Research Laboratory operates within Berthold S. Kennedy Hall at Rhodes College, conducting collaborative work on drug synthesis, biological activity assays, and structural analysis of organometallic compounds.

Nada LallousView profile

Assistant Professor

• Cancer Biology
• Biochemistry
• Biophysics
• +7 more

Dr. Nada Lallous serves as an Assistant Professor in the Department of Urologic Sciences at the University of British Columbia's Faculty of Medicine and Senior Research Scientist at the Vancouver Prostate Centre. Her research focuses on cancer drug development, particularly targeting molecular mechanisms of prostate cancer progression, metastasis, and therapeutic resistance through biochemical and biophysical approaches. Her educational background includes a M.Sc and Ph.D in Structural Biochemistry and Biophysics from the University of Strasbourg and the Institute of Genetics and Molecular and Cellular Biology (IGBMC) in France, followed by postdoctoral training at the Spanish National Cancer Research Centre (CNIO). She joined the Vancouver Prostate Centre in 2012 and was appointed Research Scientist in 2017. Dr. Lallous' research expertise spans cancer biology, protein biochemistry, drug design, and structural biology. She has extensive experience in protein characterization, X-ray crystallography (contributing to 20 Protein Data Bank structures), and preclinical validation of novel inhibitors. Key interests include androgen receptor signaling, transcription factors, biomolecular condensates, and overcoming therapeutic resistance in prostate and breast cancers through targeting molecular drivers like Lin28 and Myc. Analysis of her 2023-2025 publications reveals a dominant focus on androgen receptor (AR) biology in prostate cancer, with significant emphasis on AR variants (AR-V7), phase separation phenomena, and development of novel inhibitors targeting AR domains, Lin28-let-7 interactions, and Myc-Max dimerization. Her work integrates computational drug design, structural biology, and functional validation to address therapeutic resistance. Dr. Lallous has secured competitive funding including an NIH-SPORE grant from the National Cancer Institute to study androgen receptor variants in circulating tumor DNA. She mentors graduate students in UBC's Experimental Medicine program, including PhD candidate Louise Ramos working on bifunctional PARP-HDAC inhibitors. She actively collaborates with pharmaceutical companies on drug development projects. As manager of the protein bioengineering and biophysics group at the Vancouver Prostate Centre, Dr. Lallous is establishing a core facility to support preclinical drug validation and structural studies for cancer researchers, enabling high-throughput inhibitor screening and biophysical characterization.

James S EconomouView profile

Professor

• Cancer Immunotherapy
• Melanoma Treatment
• Dendritic Cell Vaccines
• +6 more

Dr. James S. Economou is a Professor of Surgery, Microbiology, Immunology, and Molecular Genetics (MIMG), and Molecular and Medical Pharmacology at the University of California, Los Angeles (UCLA) School of Medicine. He holds the prestigious Louis D. Beaumont Chair in Surgery and has established himself as a leading researcher in cancer immunotherapy. His work spans surgical oncology, molecular pharmacology, and immunological approaches to cancer treatment. Dr. Economou's research primarily focuses on developing novel immunotherapeutic approaches for cancer treatment, with particular emphasis on melanoma and hepatocellular carcinoma. His laboratory investigates dendritic cell-based vaccines, T-cell receptor engineering, and adoptive cell transfer therapies. He has made significant contributions to understanding how to overcome tumor resistance mechanisms and enhance the effectiveness of immunotherapies through combination approaches involving histone deacetylase inhibitors and other sensitizing agents. His work bridges basic immunological mechanisms with clinical applications, as evidenced by numerous clinical trial-related publications. Analysis of Dr. Economou's recent publications reveals a strong focus on translational immunotherapy research, particularly in T-cell engineering and adoptive cell transfer for melanoma treatment. His work shows evolution from basic immunological studies to sophisticated clinical applications, with particular attention to resistance mechanisms and strategies to overcome them. A notable trend is his investigation of dual resistance to both targeted therapies and immunotherapies, seeking combination strategies to overcome these barriers. Dr. Economou has received significant recognition through his appointment to the Louis D. Beaumont Chair in Surgery, reflecting his leadership and contributions to the field of surgical oncology. As Principal Investigator on multiple NIH-funded research projects, Dr. Economou has led substantial research efforts in cancer immunotherapy. His grants portfolio includes R01 funding for PET imaging of TCR-engineered T cells, dendritic cell-based immunotherapy for melanoma, and genetic immunotherapy for hepatocellular cancer. He has also directed training programs including the UCLA Clinical Scientist Training in Cancer Gene Medicine (K12) and the UCLA Cancer Gene Medicine Training Program (T32), indicating his commitment to mentoring the next generation of researchers. His work involves multidisciplinary collaborations across surgery, immunology, and molecular pharmacology.